Research programme: magnetic biodegradable coronary stent - Magnus Life Science

Drug Profile

Research programme: magnetic biodegradable coronary stent - Magnus Life Science

Alternative Names: Biodegradable magnetised stent - Magnus; Biomagnetic and biodegradable coronary stent - Magnus Flow; BMS - Magnus

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Magnus Life Science; University College London
  • Developer Ark Therapeutics; Magnus Life Science; University College London; Yale University
  • Class Gene therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Neuropilin-1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Coronary artery restenosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Coronary-artery-restenosis(Prevention) in European Union (Intra-arterial, Implant)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top